2C was particularly active against HCT116 p53-deficient colon carcinoma cells, verapamil-treated KB-V1Vbl cervix carcinoma cells and MCF-7 breast cancer cells, whereas 2F and 2O were highly active against multidrug-resistant HT-29 colon carcinoma cells. This evidence concerns the gene TP53 and breast cancer.